Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
– Clinical data update from a first-in-human phase 1 study of ALPN-303 in healthy adults and plans for multiple patient-based studies beginning in 2023 – – First look at data from NEON-2 study of davoceticept in combination with pembrolizumab in advanced malignancies – – Disease experts to discuss the current treatment landscape and unmet medical … [Read more…]
